Interesting study, I have to say I would take off label in a shot for the cross company collaboration:
Gilead (Sofosbuvir) and BMS (Daclatasvir) A small Phase 2 study of HCV genotype 1 (126 patients) and genotype 2 or 3 (44 patients) were treated for 12 or 24 weeks with the combination of 2 HCV polymerase inhibitors (daclatasvir and sofosbuvir) with and without ribavirin. The genotype 1 patients achieved cure rates of 96 to 98%, while genotype 2 and 3 patients achieved cure rates of 93%
Cinnamon Girl said
Nov 6, 2013
This months newsletter from the HCV Advocate website includes interesting articles on military veterans and exposure to Hep C, and the`off-label` use of prescription drugs.
Interesting study, I have to say I would take off label in a shot for the cross company collaboration:
Gilead (Sofosbuvir) and BMS (Daclatasvir)
A small Phase 2 study of HCV genotype 1 (126 patients) and genotype 2 or 3 (44 patients) were treated for 12 or 24 weeks with the combination of 2 HCV polymerase inhibitors (daclatasvir and sofosbuvir) with and without ribavirin. The genotype 1 patients achieved cure rates of 96 to 98%, while genotype 2 and 3 patients achieved cure rates of 93%
This months newsletter from the HCV Advocate website includes interesting articles on military veterans and exposure to Hep C, and the`off-label` use of prescription drugs.
http://www.hcvadvocate.org/news/newsLetter/2013/advocate1113.html#4